ATYR•aTyr Pharma’s third-quarter net loss narrowed 29% year over year to $18.26 million, while revenue fell to zero from $190,000. It had $50.3 million in cash and investments at September 30, which it said would support projected operations into late 2028 under current plans.
aTyr Pharma’s third-quarter 2026 net loss attributable to shareholders narrowed 29% year over year to $18.26 million. Revenue fell to zero from $190,000 a year earlier, while operating expenses declined 30% to $18.79 million.
Cash and investments totaled $50.3 million at September 30, supporting projected operations into late 2028 under current plans. FDA protocol alignment cleared the way for initial Phase 3 efzofitimod study activities, and the company said strategic partnerships remain a priority for advancing development.
